Cover Image
市場調查報告書

中國的人類用疫苗產業的調查、投資預測

Research and Investment Prospect of Human Vaccine Industry in China, 2014-2018

出版商 Huidian Research 商品編碼 322851
出版日期 內容資訊 英文 56 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的人類用疫苗產業的調查、投資預測 Research and Investment Prospect of Human Vaccine Industry in China, 2014-2018
出版日期: 2014年12月12日 內容資訊: 英文 56 Pages
簡介

中國擁有許可證的疫苗廠商有42家,2013年批次放行的疫苗總數約7億5,500萬次,比2012年的7億5,100萬次超過了0.53%。中國的疫苗廠商主要由國有企業、民營企業及外資企業構成。2013年疫苗批次放行數中,國有企業市場佔有率為62%依然維持首位,民營企業及外資企業的市場佔有率各為33.7%、4.23%。從2014年到2018年的中國疫苗的年複合成長率預期維持16%到18%,2018年的市場規模達到405億CNY(人民幣)。

本報告以中國的人類用疫苗產業為焦點,提供其現狀及今後的供需變化、市場趨勢、發展的影響要素、競爭環境、主要企業、投資機會等相關的評估分析彙整。

第1章 人類用疫苗產業概要

  • 定義、特徵
  • 產業鏈

第2章 中國的人類用疫苗的發展環境

  • 政策環境
  • 技術環境
    • 中國的疫苗技術的R&D
    • 關注技術分析
    • 產業技術的功能等級

第3章 人類用疫苗產業的開發

  • 人類用疫苗的發展情形
  • 人類用疫苗的需求
  • 競爭格局

第4章 中國的人類用疫苗產業的進出口

  • 進口
  • 出口

第5章 人類用疫苗產業的區分

  • 流行性腦膜炎疫苗
  • B型肝炎疫苗
  • A型肝炎疫苗
  • 日本腦炎疫苗
  • DPT疫苗
  • 流感疫苗
  • 狂犬病疫苗
  • 肺炎球菌疫苗

第6章 中國的主要人類用疫苗企業

  • Beijing Tiantan Biological Products Co., Ltd
    • 企業簡介
    • 產業實際成果
    • 疫苗產業
  • Hualan Biological Engineering Inc.
  • Liaoning Chengda Co., Ltd (LCD)
  • Walvax Biotechnology Co., Ltd
  • ChongQing ZhiFei Biological Products Co., Ltd
  • Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd
  • Changchun BCHT Biotechnology Co., Ltd

第7章 人類用疫苗投資分析

  • 投資機會
  • 投資風險
  • 進入障礙
  • 人類用疫苗產業的發展趨勢
目錄

Research and Investment Prospect of Human Vaccine Industry in China, 2014-2018, mainly studies the market, competition pattern and segmentations of human vaccine industry in China and analyzes the industry chain, import & export and key enterprises of human vaccine in China. This report analyzes the business performances of 7 key enterprises, including Beijing Tiantan Biological Products Co., Ltd, ChongQing ZhiFei Biological Products Co., Ltd, Walvax Biotechnology Co., Ltd, Liaoning Chengda Co., Ltd (LCD) etc.

As one of powerful vaccine manufacturing countries in world, China has 42 vaccine manufacturers with approval license. In 2013, the total of lot release quantity of vaccines was about 755 million doses, increasing by 0.53% over the 751 million doses in 2012. Vaccine manufacturers mainly consist of state-owned enterprises, private enterprises and foreign-funded enterprises in China. Seeing from the lot release quantity of vaccine in 2013, the state-owned enterprises still take the leading position in vaccine market, with market shares of 62%, followed by private enterprises and foreign-funded enterprises successively, with market shares of 33.77% and 4.23% respectively.

Most of market of type I vaccines is still dominated by state-owned enterprises, including 6 largest institutes of China National Biotec-Group Company Limited and Changchun Keygen Biological Products Co., Ltd. Private enterprises take half of market shares of type II vaccines, the representative enterprises include: ChongQing ZhiFei Biological Products Co., Ltd, and Walvax Biotechnology Co., Ltd etc. While the international enterprises have definite advantages in respects of high-end vaccines and multivalent vaccines, taking pneumococcal vaccines for instance, only one conjugate vaccine is available, say: Pneumococcal 7-Valent Conjugate Vaccine produced by Pfizer. Although, at present, several enterprises are conducting studies on pneumococcal conjugate vaccines, it is still long to launch on the market, with huge uncertainties.

In 2014-2018, the average growth rate of vaccine in China will maintain at 16%-18%. The main driving factors include: implement of national vaccine immunization plan, increasing receptivity of vaccine by people, rising trend of initiative vaccination and increase of type III vaccines application etc. It can be expected that the market scale of vaccine will hit CNY 40.5 billion in 2018.

Table of Contents

1. Overview of Human Vaccine Industry

  • 1.1. Definition and Characteristics
    • 1.1.1. Industry Definition
    • 1.1.2. Product Classification
  • 1.2. Industry Chain
    • 1.2.1. Upstream Market
    • 1.2.2. Downstream Market

2. Development Environment of Human Vaccine in China

  • 2.1. Policy Environment
  • 2.2. Technical Environment
    • 2.2.1. R&D of Vaccines Technology in China
    • 2.2.2. Hot Technologies Analysis
    • 2.2.3. Active Degree of Industry Technology

3. Development of Human Vaccine Industry

  • 3.1. Development Status Quo of Human Vaccine
    • 3.1.1. Overview of Market
    • 3.1.2. Supply in 2013
  • 3.2. Demand of Human Vaccine
    • 3.2.1. Demand in 2013
    • 3.2.2. Demand Forecast, 2014-2018
  • 3.3. Competition Pattern

4. Import and Export of Human Vaccine Industry in China

  • 4.1. Import
    • 4.1.1. Import Data
    • 4.1.2. Import Sources, Jan.-Sept 2014
  • 4.2. Export
    • 4.2.1. Export Data
    • 4.2.2. Export Destinations, Jan.-Sept 2014

5. Segmented Industries of Human Vaccine

  • 5.1. Epidemic Meningitis Vaccine
    • 5.1.1. Industry Status Quo
    • 5.1.2. Segmentations
  • 5.2. Hepatitis B Vaccine
    • 5.2.1. Market Status Quo
    • 5.2.2. Supply
    • 5.2.3. Demand
  • 5.3. Hepatitis A Vaccine
    • 5.3.1. Supply
    • 5.3.2. Demand
  • 5.4. Encephalitis B Vaccine
    • 5.4.1. Supply
    • 5.4.2. Demand
  • 5.5. DPT Vaccine
    • 5.5.1. Supply
    • 5.5.2. Demand
  • 5.6. Influenza Vaccine
    • 5.6.1. Supply
    • 5.6.2. Demand
  • 5.7. Rabies Vaccine
    • 5.7.1. Overview of Market
    • 5.7.2. Supply
    • 5.7.3. Demand
  • 5.8. Pneumococcal Vaccine
    • 5.8.1. Supply
    • 5.8.2. Demand

6. Key Human Vaccine Enterprises in China

  • 6.1. Beijing Tiantan Biological Products Co., Ltd
    • 6.1.1. Company Profile
    • 6.1.2. Business Performance
    • 6.1.3. Vaccine Business
  • 6.2. Hualan Biological Engineering Inc.
    • 6.2.1. Company Profile
    • 6.2.2. Business Performance
    • 6.2.3. Vaccine Business
  • 6.3. Liaoning Chengda Co., Ltd (LCD)
    • 6.3.1. Company Profile
    • 6.3.2. Business Performance
    • 6.3.3. Vaccine Business
  • 6.4. Walvax Biotechnology Co., Ltd
    • 6.4.1. Company Profile
    • 6.4.2. Business Performance
    • 6.4.3. Vaccine Business
  • 6.5. ChongQing ZhiFei Biological Products Co., Ltd
    • 6.5.1. Company Profile
    • 6.5.2. Business Performance
    • 6.5.3. Vaccine Business
  • 6.6. Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd
    • 6.6.1. Company Profile
    • 6.6.2. Vaccine Business
  • 6.7. Changchun BCHT Biotechnology Co., Ltd
    • 6.7.1. Company Profile
    • 6.7.2. Vaccine Business

7. Investment Analysis on Human Vaccine

  • 7.1. Investment Opportunities
    • 7.1.1. Policy Support
    • 7.1.2. Vast Consumption Market
  • 7.2. Investment Risks
    • 7.2.1. Market Competition
    • 7.2.2. Quality Accidents
    • 7.2.3. Product R&D
    • 7.2.4. Core Technician Drain
  • 7.3. Entry Barrier
    • 7.3.1. Administrative Barrier
    • 7.3.2. Capital Barrier
    • 7.3.3. Technical Renovation Barrier
  • 7.4. Development Trend of Human Vaccine Industry
    • 7.4.1. International Blockbuster Products Will be Innovation Goal of Chinese Enterprises
    • 7.4.2. Chinese-foreign Joint Venture Will Become Important Enterprise Development Mode
    • 7.4.3. Children Conjugate Vaccine Will Become Trend
Back to Top